Scholar Rock Holding Corporation (SRRK) SEC Filings & Earnings Calls

Post-marketing safety requirements may impose additional costs and regulatory scrutiny.

“FDA outlined post-marketing requirement for pregnancy safety study and fracture alert reports.”

Fractures occurred in 9% of ISEMBYLD-treated patients vs 2% placebo.

“Fractures occurred in 9% of patients treated with ISEMBYLD 10 mg/kg vs. 2% in placebo.” · word for word

Regulatory approval risk

“In September 2025, the Company received a Complete Response Letter ("CRL") from the FDA related to observations identified during an FDA inspection of a third-party fill-finish facility.” · word for word

Commercialization risk

“If apitegromab is approved by the FDA or EMA, the Company expects to initiate a commercial product launch in the applicable jurisdictions upon approval.” · word for word

Financing risk

“The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop and seek regulatory approval for its product candidates.” · word for word

Manufacturing risk

“The CRL did not cite any other approvability concerns, including apitegromab’s efficacy and safety data or the third-party drug substance manufacturer.” · word for word

Regulatory risk: FDA approval not guaranteed; reliance on Catalent facility inspection.

“FDA inspection classification of Catalent Indiana is pending.”

No revenue; pre-commercial biotech with significant cash burn.

“The Company did not record any revenue for the quarters ended June 30, 2026 and 2025.” · word for word

Dilution risk from ongoing ATM sales.

“Up to $200M additional shares may be sold, diluting existing shareholders.”

FDA approval delay for apitegromab

“In September 2025, the Company received a Complete Response Letter ("CRL") from the FDA related to observations identified during an FDA inspection of a third-party fill-finish facility.” · word for word

Dependence on third-party fill-finish facility

“The observations were related to the facility and were not specific to apitegromab.” · word for word

Significant operating losses and negative cash flow

“Net loss $105,510 for the three months ended March 31, 2026 compared to $74,723 for the three months ended March 31, 2025.”

Pre-revenue biotech with accumulated deficit

“Net Income/(Loss) (6) (in millions) ... $ ( 378 )”

Key person dependence on new CEO and executive team

“David Hallal has served as Chief Executive Officer of Scholar Rock since April 2025” · word for word

Regulatory risk remains; FDA approval not guaranteed and timeline could be extended.

“Previous Complete Response Letter; resubmission dependent on FDA reinspection and facility qualifications.”

Regulatory approval risk

“In September 2025, we received a CRL from the FDA related to observations identified during a routine general site inspection of a third-party fill-finish facility.” · word for word

Commercialization risk

“Our ability to successfully build a commercial infrastructure to launch and market apitegromab, or otherwise provide access to apitegromab, if and when it is approved or receives pricing or reimbursement approval.” · word for word

Funding risk

“Our ability to obtain, generally or on terms acceptable to us, funding for our operations, including funding necessary to commercialize, if approved, apitegromab and complete further development of our current and future product candidates.” · word for word

BLA resubmission dependent on FDA reinspection of Catalent facility; regulatory risk.

“BLA resubmission upon successful FDA reinspection of Catalent Indiana.”

Preliminary financial data subject to adjustment; no revenue or earnings disclosed.

“This financial information is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition” · word for word

FDA warning letter at Catalent facility could delay BLA resubmission and launch of apitegromab.

“Catalent Indiana received a warning letter from the FDA... the Company continues to anticipate resubmission... in 2026.” · word for word

FDA Approval Delay

“In September 2025, the Company received a Complete Response Letter ("CRL") from the FDA related to observations identified during a routine general site inspection of a third-party fill-finish facility.” · word for word

Third-Party Manufacturing Dependency

“The observations were site-related and not specific to apitegromab. The CRL did not cite any other approvability concerns, including apitegromab's efficacy and safety data or the third-party drug substance manufacturer.” · word for word

Cash Burn Rate

“Net cash used in operating activities was $224.5 million for the nine months ended September 30, 2025.”

No Approved Products / No Revenue

“No revenues have been recorded from the sale of any commercial product.” · word for word

Dilution Risk

“The Company sold 2,767,000 shares of its common stock under the ATM program during the nine months ended September 30, 2025, generating net proceeds of $91.7 million.” · word for word

Regulatory and manufacturing risks for apitegromab BLA resubmission; reliance on Catalent facility readiness.

Potential dilution from $200M ATM offering.

“Up to $200M in common stock may be sold.”